Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis
Authors' conclusion
GLP-1 RAs were found to be beneficial for not only weight loss but also reduction in risk factors for cardiovascular disease such as BP and lipid profile. Consistent beneficial results were observed across the various subtypes of GLP-1 RAs.
Study context
- Population
- Individuals with obesity and without diabetes15 trials
- Comparison
- GLP-1 RAs vs comparator
- Outcome
- Weight loss
Methodological detailsrandom-effects meta-analysis, Search of PubMed, Scopus and Cochrane Central; 7535 articles yielded
- Random-effects meta-analysis
- Search of PubMed, Scopus and Cochrane Central; 7535 articles yielded
Pooled result
As reported in the abstract
Significant weight loss with GLP-1 RAs (MD, P <.01)
−8.77 kg
Further pooled results
Systolic blood pressure (BP)
- Improved with GLP-1 RAs (MD, P <.01)
- −4.13 mm Hg
Diastolic BP
- Improved with GLP-1 RAs (MD, P <.01)
- −1.39 mm Hg
Lipid profile
mg/dL
- Triacylglycerol (SMD, P <.01)
- −0.99
- Total cholesterol (SMD, P <.01)
- −0.73
- Very low-density lipoprotein (SMD, P <.01)
- −1.11
- Low-density lipoprotein (SMD, P <.01)
- −0.27
- High-density lipoprotein increased (SMD, P <.01)
- 0.11
Safety
- GLP-1 RAs associated with an increased risk of gastrointestinal adverse events
Original publication
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis. Endocr Pract. Published 27 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →